Halozyme Therapeutics Investor Presentation — January 2017

Document content

Study 202 Overall Results

1 Copyright © 2017 Halozyme, Inc.Study 202 Design Overview

2•Phase 2, randomized, multicenter study

•Patients with stage IV (metastatic ), previously untreated PDA

•Primary & Secondary PFS Endpoint:

–80% power at 2- sided alpha level of 0.1

CR, complete response; DCR, disease control rate; DoR, duration of response; HA, hyaluronan; KPS, Karnofsky performance status; ORR, objective response rate; OS, overall survival;

PDA, pancreatic ductal adenocarcinoma; PFS, progression- free survival; PR, partial response; SD, stable disease.Halozyme/Ventana HA Companion Diagnostic (CDx)

3Determining HA Status

•Novel CDx to identify patients with HA-High PDA tumors

•An affinity histochemistry assay with a scoring algorithm based on the HA

staining pattern area in the extracellular matrix (ECM) over the entire tumor

•PDA tumors are HA -High when the HA score is ≥50%Study 202 Study Timeline

Mar April Aug Feb Dec

• Training Set for CDx

• Develop Ventana HA scoring algorithm and

• ~40% HA High patients treated on PAG arm

discontinued PEGPH20 at the clinical hold

• Presented at ASCO 2016

•Validation Set for CDx

•Prospectively validate Ventana HA scoring

algorithm and cut -point used in Phase 3 study

•To be presented at Scientific Forum 2017

Follow up Data ReadoutStudy 202: Modifications Since Stage 1 Clinical Hold

5Statistical Analysis

Plan Planned Analysis Populations:

-Intent -to-Treat: Combined Stage 1 + Stage 2 efficacy analyses

-Efficacy Evaluable (requires post baseline assessment): Primary

-Treated population: Separate analyses of Stage 1 and Stage 2

PFS event definition to include deaths occurring within 14 days of last

Preview truncated — download the full document for the complete content.